Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Heron Therapeutics
ClinicalTrials.gov Identifier:
NCT01416259
First received: August 10, 2011
Last updated: October 24, 2012
Last verified: October 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2011
  Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)